Evogene Ltd. (NASDAQ:EVGN – Get Free Report)’s stock price crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.72 and traded as low as $1.00. Evogene shares last traded at $1.01, with a volume of 11,485 shares traded.
Analysts Set New Price Targets
A number of research analysts have commented on EVGN shares. StockNews.com started coverage on shares of Evogene in a research report on Friday. They set a “sell” rating on the stock. Alliance Global Partners reaffirmed a “buy” rating on shares of Evogene in a report on Friday, March 7th.
View Our Latest Research Report on EVGN
Evogene Trading Down 5.4 %
Evogene (NASDAQ:EVGN – Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.78. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. The firm had revenue of $1.61 million during the quarter, compared to the consensus estimate of $3.63 million. During the same quarter in the previous year, the company posted ($1.30) earnings per share.
Institutional Investors Weigh In On Evogene
A hedge fund recently bought a new stake in Evogene stock. Jane Street Group LLC bought a new position in Evogene Ltd. (NASDAQ:EVGN – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 21,345 shares of the biotechnology company’s stock, valued at approximately $40,000. Jane Street Group LLC owned about 0.40% of Evogene at the end of the most recent reporting period. 10.40% of the stock is owned by institutional investors and hedge funds.
Evogene Company Profile
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Featured Stories
- Five stocks we like better than Evogene
- 5 Top Rated Dividend Stocks to Consider
- Joby Aviation: Operational Momentum vs. Market Sentiment
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Broadcom’s Big Outperformance Shows Strength Amid Tariff Decline
- 3 Warren Buffett Stocks to Buy Now
- Carvana: Can Turnaround Strength Outdrive Market Headwinds?
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.